SCA
TGTX icon

Secor Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Secor Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-30,820
Closed -$187K – 661
2016
Q2 		$187K Buy
+30,820
New +$251K 0.02% 544

Other funds holding TGTX

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Secor Capital Advisors's TGTX Position: Q3 2016 in Review

Secor Capital Advisors sold out of TG Therapeutics (TGTX) in Q3 2016, closing a stake of 30,820 shares — an estimated $187K sold.

Secor Capital Advisors first reported a position in TGTX in Q2 2016 and held it in 1 quarter. The position peaked at $187K in Q2 2016. 77 funds tracked by Wall St. Rank hold TGTX as of Q3 2016.

  • Secor Capital Advisors reported no remaining TG Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Secor Capital Advisors sold 30,820 TG Therapeutics shares in Q3 2016, an estimated $187K.
  • Secor Capital Advisors first reported a position in TG Therapeutics in Q2 2016 and held it in 1 quarter.
  • Secor Capital Advisors's TG Therapeutics position peaked at $187K in Q2 2016.
  • 77 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2016.

Based on Secor Capital Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.